Mechanistic Modelling Identifies and Addresses the Risks of Empiric Concentration-Guided Sorafenib Dosing

Abstract

The primary objective of this study is to evaluate the capacity of concentration-guided sorafenib dosing protocols to increase the proportion of patients that achieve a sorafenib maximal concentration (Cmax) within the range 4.78 to 5.78 μg/mL. A full physiologically based pharmacokinetic model was built and validated using Simcyp® (version 19.1). The model was used to simulate sorafenib exposure in 1000 Sim-Cancer subjects over 14 days. The capacity of concentration-guided sorafenib dose adjustment, with/without model-informed dose selection (MIDS), to achieve a sorafenib Cmax within the range 4.78 to 5.78 μg/mL was evaluated in 500 Sim-Cancer subjects. A multivariable linear regression model incorporating hepatic cytochrome P450 (CYP) 3A4 abundance, albumin concentration, body mass index, body surface area, sex and weight provided robust prediction of steady-state sorafenib Cmax (R2 = 0.883; p < 0.001). These covariates identified subjects at risk of failing to achieve a sorafenib Cmax ≥ 4.78 μg/mL with 95.0% specificity and 95.2% sensitivity. Concentration-guided sorafenib dosing with MIDS achieved a sorafenib Cmax within the range 4.78 to 5.78 μg/mL for 38 of 52 patients who failed to achieve a Cmax ≥ 4.78 μg/mL with standard dosing. In a simulation setting, concentration-guided dosing with MIDS was the quickest and most effective approach to achieve a sorafenib Cmax within a designated range.

A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution

“…PBPK modelling and simulation is an established tool to support drug discovery and development and is a core element of the regulatory approval process in many jurisdictions [18]. Recent studies have further demonstrated the potential role of PBPK in predicting covariates affecting variability in drug exposure resulting from differences in patient characteristics [14,15,45], giving rise to the intriguing potential for this platform to support model-informed precision dosing [46,47]. This model provides an important foundation for establishing a PK/PD relationship for epirubicin; however, further work on population-based dose predictive modelling is imperative to inform optimal therapeutic windows for individualized dosage.…”

Development and Evaluation of a Prototype Mobile Application for Intravenous Drug Dose Calculation in Overweight and Obese Thai Children: Precision Dosing in Practice

“…The core principle underlying precision dosing involves the comprehensive consideration of inter and intraindividual variability factors, encompassing genetic polymorphism, age, weight, organ function, and concurrent medication usage. 13,14 By methodically incorporating these influential variables, precision dosing strategies strive to optimize drug administration, tailored to the distinctive characteristics of individual patients, thereby enhancing the efficacy and safety of treatment interventions. 14 The last decade has witnessed a remarkable societal transformation driven by technological advancements.…”

Special Issue “Anticancer Drugs 2021”

“…Inconsistencies in treatment efficacy and tolerability may be attributed to variability in sorafenib exposure over time. Ruanglertboon et al developed a concentration-guided sorafenib dosing protocol to increase the proportion of patients that achieve a sorafenib C max within the required range by using a model to simulate sorafenib exposure [8].…”